Friede, Tim, Prof. Dr.

Professor of Biostatistics

  • 1998 Dipl.-Math. (Master's degree in Mathematics), University of Karlsruhe, Germany
  • 2001 (PhD), University of Heidelberg, Germany
  • 2001-2004 PostDoc / lecturer, Dept. of Mathematics and Statistics, Lancaster University, UK
  • 2004-2006 Expert Statistical Methodologist, Novartis Pharma AG, Basel, Switzerland
  • 2006-2009 Associate Professor of Medical Statistics, University of Warwick, UK
  • since 1/2010 Professor of Biostatistics and Director, Dept. of Medical Statistics, University Medical Center Göttingen

Major Research Interests

Clinical biostatistics including designs for clinical trials (in particular flexible adaptive designs) and systematic reviews / meta-analyses.

Homepage Department/Research Group:

Selected Recent Publications

  • Hellmann-Regen J, Clemens V, Grözinger M, Kornhuber J, Reif A, Prvulovic D, Goya-Maldonado R, Wiltfang J, Gruber O, Schüle C, Padberg F, Ising M, Uhr M, Friede T, Huber C, Manook A, Baghai TC, Rupprecht R, Heuser I (2022) Effect of Minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized controlled trial. JAMA Network Open 5(9): e2230367.
  • Stegherr R, Schmoor C, Beyersmann J, Rufibach K, Jehl V, Brückner A, Eisele L, Künzel T, Kupas K, Langer F, Leverkus F, Loos A, Norenberg C, Voss F, Friede T (2021) Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) - estimation of adverse event risks. Trials 22: 420.
  • Cole J, Raffel J, Friede T, Eshaghi A, Brownlee W, Chard C, De Stefano N, Enzinger C, Pipramer L, Filippi M, Gasperini C, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Stromillo ML, Uitdehaag B, Vrenken H, Barkhof F, Nicholas R, Ciccarelli O on behalf of the MAGNIMS study group (2020) Longitudinal assessment of multiple sclerosis with the brain-age paradigm. Annals of Neurology 88: 93–105.
  • Stork L, Ellenberger D, Ruprecht K, Reindl M, Beißbarth T, Friede T, Kümpfel T, Gloth M, Paul F, Brück W, Metz I (2020) Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Acta Neuropathologica 139: 547-564.
  • Friede T, Pohlmann H, Schmidli H (2019) Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. Pharmaceutical Statistics 18: 351–365.
  • Nicholas RS, Han E, Raffel J, Chataway J, Friede T (2019) Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: a systematic review and meta-analysis of 43 randomized placebo-controlled trials. Multiple Sclerosis Journal 25: 1462–1471.
  • Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CF, Brück W, Metz I (2018) Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurology 75: 428-435.
  • Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I (2017) Doxycycline in early CJD ? double-blinded randomized phase II and observational study. Journal of Neurology, Neurosurgery & Psychiatry 88: 119–125
  • Raffel J, Wallace A, Gveric D, Reynolds R, Friede T, Nicholas R (2017) Patient-reported outcomes and survival in multiple sclerosis: a 10-year retrospective cohort study using the MSIS-29. PLOS Medicine 14(7): e1002346
  • Gold SM, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr DC, Otto C (2017) Control conditions for randomized trials of behavioral interventions in psychiatry: A decision framework. Lancet Psychiatry 4: 725–732.
  • Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I on behalf of NEMOS (Neuromyelitis Optica Study Group) (2017) Immunotherapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry 88(8): 639-647
  • Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C & the DeNoPa Study Group (2015) Monitoring of thirty marker candidates in early Parkinson's disease as progression markers. Neurology 87: 168-77.
  • Metz I, Beißbarth T, Ellenberger D, Pache F, Stork L, Ringelstein M, Aktas O, Jarius S, Wildemann BT, Dihazi H, Friede T, Brück W, Ruprecht K, Paul F (2015) Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation 2016;3:e204; doi: 10.1212/NXI.0000000000000204
  • Chataway J, Friede T (2016) The N-MOmentum trial: building momentum to advance trial methodology in a rare disease. Multiple Sclerosis Journal 22: 852?853.
  • Unkel S, Röver C, Stallard N, Benda N, Posch M, Zohar S, Friede T (2016): Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions, Orphanet Journal of Rare Diseases 11:16.
  • Stellmann JP, Stürner KH, Young KL, Siemonsen S, Friede T, Heesen C (2015) Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts - is there a place for baseline-to-treatment studies in MS? PLoS ONE 10(2): e0116559. doi:10.1371/journal.pone.0116559
  • Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Friede T, Zerr I (2015) CSF Apolipoprotein E concentration and progression of Alzheimer?s Disease. Journal of Alzheimer?s Disease 43(4): 1229-1236.
  • Huppke B, Ellenberger D, Rosewich H, Friede T, Gärtner J, Huppke P (2014) Clinical presentation of pediatric multiple sclerosis before puberty. European Journal of Neurology 2: 441-446
  • Schmidt C, Wolff M, von Ahsen N, Lange K, Friede T, Zerr I (2014) CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease. Journal of Clinical Neuroscience (in press)
  • Schmidt C, Becker H, Peter C, Lange K, Friede T, Zerr I (2014) Plasma prion protein concentration and progression of Alzheimer's disease. Prion (in press)
  • Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Friede T, Zerr I (2014) CSF Apolipoprotein E concentration and progression of Alzheimer's Disease. Journal of Alzheimer?s Disease (in press)
  • Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar K, Lohmann K, Klein C, Schlossmacher M, Kohnen R, Friede T, Trenkwalder C (2013) Non-motor and diagnostic findings in de novo Parkinson's disease subjects of the DeNoPa cohort. Neurology 81: 1226-1234
  • Steinvorth SM, Röver C, Schneider S, Nicholas R, Straube S, Friede T (2013) Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression. Multiple Sclerosis Journal 19: 1580-1586
  • Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T (2012) Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis Journal 18: 1290-1296
  • Friede T, Parsons N, Stallard N, Todd S, Valdés-Márquez E, Chataway J, Nicholas R (2011) Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine 30: 1528-1540
  • Chataway J, Nicholas R, Todd, S, Parsons N, Todd S, Miller D, Valdés-Márquez E, Stallard N, Friede T (2011) A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis 17: 81-88
  • Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdés-Márquez E, Chataway J (2010) Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis. Drug Information Journal 44: 713-718
  • Friede T, Schmidli H (2010) Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicine 29: 1145-1156
  • Rog DJ, Nurmikko TJ, Friede T, Young CA (2007) Validation and reliability of the neuropathic pain scale (NPS) in multiple sclerosis. Clinical Journal of Pain 23: 473–481